Lanlan J. Li

Lanzhou, 730030, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Targeting the FTO-ACSL4 Pathway: A Novel Mechanism for Sanguinarine Chloride-Induced Ferroptosis in Endometrial Cancer.

Targeting the FTO-ACSL4 Pathway: A Novel Mechanism for Sanguinarine Chloride-Induced Ferroptosis in Endometrial Cancer.

Journal: Biomedicines
Published: February 04, 2026

Sanguinarine chloride exerts its antitumor effects on enzalutamide-resistant prostate cancer by inhibiting cell proliferation and promoting senescence via targeting AR signaling.

Sanguinarine chloride exerts its antitumor effects on enzalutamide-resistant prostate cancer by inhibiting cell proliferation and promoting senescence via targeting AR signaling.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: December 21, 2025

Quantitative proteomic analysis reveals different characteristics of bladder cancer cells after exposure to bisphenol A.

Quantitative proteomic analysis reveals different characteristics of bladder cancer cells after exposure to bisphenol A.

Journal: FEBS open bio
Published: September 29, 2025

Targeting EGFR with sanguinarine chloride: a novel approach to bladder cancer therapy.

Targeting EGFR with sanguinarine chloride: a novel approach to bladder cancer therapy.

Journal: Biochemical pharmacology
Published: July 17, 2025

TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer.

TAK-901 Targeted Inhibition of EGFR Activates Transcription Factor FOXO, Causing Cell-cycle Arrest and Apoptosis in Bladder Cancer.

Journal: Molecular cancer therapeutics
Published: May 07, 2025

Evodiamine induces ferroptosis in prostate cancer cells by inhibiting TRIM26-mediated stabilization of GPX4.

Evodiamine induces ferroptosis in prostate cancer cells by inhibiting TRIM26-mediated stabilization of GPX4.

Journal: Chinese medicine
Published: March 22, 2025

Ro 31-8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo.

Ro 31-8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo.

Journal: FEBS open bio
Published: March 10, 2025

TAK-901, a novel EPHA2 inhibitor as a therapeutic strategy against prostate cancer.

TAK-901, a novel EPHA2 inhibitor as a therapeutic strategy against prostate cancer.

Journal: Cellular signalling
Published: December 26, 2024

Bladder Cancer Patients with Elevated SPRR1B Expression Experiencing a Poor Prognosis.

Bladder Cancer Patients with Elevated SPRR1B Expression Experiencing a Poor Prognosis.

Journal: Archivos espanoles de urologia
Published: July 10, 2024

SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway.

SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway.

Journal: Communications biology
Published: February 25, 2024

SRT1720 inhibits bladder cancer cell progression by impairing autophagic flux.

SRT1720 inhibits bladder cancer cell progression by impairing autophagic flux.

Journal: Biochemical pharmacology
Published: October 26, 2023

Sanguinarine chloride induces ferroptosis by regulating ROS/BACH1/HMOX1 signaling pathway in prostate cancer.

Sanguinarine chloride induces ferroptosis by regulating ROS/BACH1/HMOX1 signaling pathway in prostate cancer.

Journal: Chinese medicine
Published: October 09, 2023
Showing 1-12 of 24

Last Updated: 09/26/2026